Screener
Enliven Therapeutics ELVN Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 4,196 | 3,196 |
| Other expense | — | (47) |
| Total other income (expense), net | 4,196 | 3,149 |
| Net loss | (23,627) | (28,544) |
| Other comprehensive income (loss): | ||
| Net unrealized losses on marketable securities | (716) | (71) |
| Comprehensive loss | $(24,343) | $(28,615) |
| Net loss per share, basic and diluted | $(0.38) | $(0.57) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's net income?
- Enliven Therapeutics (ELVN) reported net income of -$23.63M in Q1 2026.
- How has Enliven Therapeutics's net income changed year-over-year?
- Enliven Therapeutics's net income increased by 17.2% year-over-year, from -$28.54M to -$23.63M.
- What is the long-term trend for Enliven Therapeutics's net income?
- Over 4 years (2021 to 2025), Enliven Therapeutics's net income has grown at a 19.2% compound annual growth rate (CAGR), from -$51.38M to -$103.69M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Enliven Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude